OutLyzer: software for extracting low-allele-frequency tumor mutations from sequencing background noise in clinical practice.
Highlighting tumoral mutations is a key step in oncology for personalizing care. Considering the genetic heterogeneity in a tumor, software used for detecting mutations should clearly distinguish real tumor events of interest that could be predictive markers for personalized medicine from false positives. OutLyzer is a new variant-caller designed for the specific and sensitive detection of mutations for research and diagnostic purposes. It is based on statistic and local evaluation of sequencing background noise to highlight potential true positive variants. 130 previously genotyped patients were sequenced after enrichment by capturing the exons of 22 genes. Sequencing data were analyzed by HaplotypeCaller, LofreqStar, Varscan2 and OutLyzer. OutLyzer had the best sensitivity and specificity with a fixed limit of detection for all tools of 1% for SNVs and 2% for Indels. OutLyzer is a useful tool for detecting mutations of interest in tumors including low allele-frequency mutations, and could be adopted in standard practice for delivering targeted therapies in cancer treatment.
Department of Cancer Biology and Genetics, CCC François Baclesse, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Caen, France.|Inserm U1079, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Rouen, France.
Etienne
E
Muller
Department of Cancer Biology and Genetics, CCC François Baclesse, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Caen, France.
Nicolas
N
Goardon
Department of Cancer Biology and Genetics, CCC François Baclesse, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Caen, France.
Baptiste
B
Brault
Department of Cancer Biology and Genetics, CCC François Baclesse, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Caen, France.
Antoine
A
Rousselin
Department of Cancer Biology and Genetics, CCC François Baclesse, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Caen, France.
Germain
G
Paimparay
Department of Cancer Biology and Genetics, CCC François Baclesse, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Caen, France.
Angelina
A
Legros
Department of Cancer Biology and Genetics, CCC François Baclesse, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Caen, France.
Robin
R
Fouillet
Department of Cancer Biology and Genetics, CCC François Baclesse, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Caen, France.
Olivia
O
Bruet
Department of Cancer Biology and Genetics, CCC François Baclesse, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Caen, France.
Aurore
A
Tranchant
Department of Cancer Biology and Genetics, CCC François Baclesse, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Caen, France.
Florian
F
Domin
Department of Cancer Biology and Genetics, CCC François Baclesse, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Caen, France.
Chankannira
C
San
Department of Cancer Biology and Genetics, CCC François Baclesse, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Caen, France.
Céline
C
Quesnelle
Inserm U1079, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Rouen, France.|Genetic Department, Rouen University Hospital, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Rouen, France.|Rouen University, France.
Thierry
T
Frebourg
Department of Cancer Biology and Genetics, CCC François Baclesse, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Caen, France.
Agathe
A
Ricou
Department of Cancer Biology and Genetics, CCC François Baclesse, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Caen, France.|Inserm U1079, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Rouen, France.|Caen University, France.
Sophie
S
Krieger
Department of Cancer Biology and Genetics, CCC François Baclesse, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Caen, France.|Inserm U1079, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Rouen, France.
Dominique
D
Vaur
Department of Cancer Biology and Genetics, CCC François Baclesse, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Caen, France.|Inserm U1079, Genomic and Personalized Medicine in Cancer and Neurological Disorders Unit, Rouen, France.
Laurent
L
Castera
D019295:Computational Biology / Q000379:methods*; D005091:Exons; D005787:Gene Frequency; D005838:Genotype; D059014:High-Throughput Nucleotide Sequencing / Q000379:methods*; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000235:genetics*; D057285:Precision Medicine; D017422:Sequence Analysis, DNA / Q000379:methods*; D012984:Software
bioinformatics; oncology; precision medicine; somatic mutation; variant-caller